Trial Profile
Efficacy and Safety of Single Agent Pan-HER Inhibitor Dacomitinib in the Treatment of Locally Advanced Unresectable or Metastatic Squamous Cell Cancer of the Skin or With Clinical Contraindication to Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DACOMINT14
- 04 May 2018 Primary endpoint (Response rate to Dacomitinib) has not been met, according to the results published in the European Journal of Cancer.
- 04 May 2018 Status changed from active, no longer recruiting to completed, according to the results published in the European Journal of Cancer.
- 04 May 2018 Results published in the European Journal of Cancer